<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95625">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01720056</url>
  </required_header>
  <id_info>
    <org_study_id>EC 067/2012</org_study_id>
    <nct_id>NCT01720056</nct_id>
  </id_info>
  <brief_title>Verapamil vs Steroid to Prevent Keloid Recurrence</brief_title>
  <official_title>Assessment of Verapamil as an Adjunct for Prevention of Keloid Recurrence After Surgical Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Western Australia</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Keloid scarring is a severe cosmetic and painful disease of the skin. The gold standard
      treatment is yet to be clarified. This randomized clinical pilot study will compare the
      effects of two local treatments for preventing keloid recurrence after surgical removal;
      steroid and verapamil.

      Study hypothesis: Intralesional therapy with the calcium antagonist verapamil has equal
      treatment efficacy as steroid injection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Keloid recurrence</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vancouver Scar Scale Score</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Keloid Scars</condition>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Verapamil 2.5 mg/mL injection sc intralesionally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kenalog 10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kenalog 10 mg/mL injection sc intralesionally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <arm_group_label>Verapamil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kenalog 10</intervention_name>
    <arm_group_label>Kenalog 10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient undergoing surgical removal of keloid

          -  Patient 18 years old or greater

          -  Length of excisional scar after surgical removal of keloid between 2 and 10 cm

        Exclusion Criteria:

          -  Keloid in face or hands

          -  Pregnancy or lactation

          -  Dementia

          -  Any heart or pulmonary condition

          -  Systemic treatment with beta-blockers, ACE-inhibitors or calcium antagonists

          -  Systemic corticosteroidal therapy

          -  Intralesional steroid treatment within 2 months of surgery to remove keloid

          -  Flap surgery

          -  Lesions to face, hands and other cosmetically sensitive areas
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fiona M Wood, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Western Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia L. Danielsen, MD, PhD</last_name>
    <phone>0448697737</phone>
    <email>patriciadanielsen@yahoo.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hilary Wallace, Dr.</last_name>
    <email>hilary.wallace@uwa.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona M Wood, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Patricia L. Danielsen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hilary Wallace, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzanne Rea, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 30, 2012</lastchanged_date>
  <firstreceived_date>October 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Western Australia</investigator_affiliation>
    <investigator_full_name>Fiona M. Wood</investigator_full_name>
    <investigator_title>Prof. Wood</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keloid</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
